Form 4: Protagenic Therapeutics Director Acquires Options

Director Khalil Barrage acquired 22,500 options in Protagenic Therapeutics (PTIX) on March 25, 2024, at an exercise price of $1.74.

Summary

• Khalil Barrage, a director of Protagenic Therapeutics, acquired 22,500 options of PTIX common stock on March 25, 2024.
• The exercise price of these options is $1.74.
• The options vest monthly over 24 months starting from the grant date, with full acceleration upon a change of control.
• The options expire on March 25, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of option grants to a director. The acquisition of options can be seen as a slightly positive sign, indicating confidence, but it's not a major event.

Positives

• The acquisition of options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of a director's stock ownership and option grants, common in the pharmaceutical industry where equity compensation is frequently used.

Comparison to Industry Standards

• Option grants to directors are a common practice in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedule of monthly over 24 months is fairly standard.
• Full acceleration upon a change of control is also a typical provision to protect the director's interests in the event of a merger or acquisition.

Stakeholder Impact

• The acquisition of options by a director could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

options, director, acquisition, PTIX, Protagenic Therapeutics, beneficial ownership, Form 4